ADC Therapeutics (ADCT) Equity Ratio (2021 - 2026)

ADC Therapeutics has disclosed Equity Ratio across 6 years of filings, most recently posting 0.74 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.74, up 15.08% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.74 (up 15.08% YoY), and the FY2025 annual result was 0.58, up 8.63% from the prior year.
• Equity Ratio came in at 0.74 for Q1 2026 at ADC Therapeutics, down from 0.58 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.16 in Q4 2022 to a low of 0.87 in Q1 2025.
• The 5-year median for Equity Ratio is 0.62 (2025), against an average of 0.55.
• Across the five-year window, Equity Ratio plunged 358.16% in 2023 and gained 15.08% in 2026, its largest moves.
• ADC Therapeutics' Equity Ratio stood at 0.16 in 2022, then slumped by 358.16% to 0.42 in 2023, then slumped by 50.62% to 0.63 in 2024, then rose by 8.63% to 0.58 in 2025, then decreased by 29.08% to 0.74 in 2026.
• The last three Equity Ratio figures came in at 0.74 (Q1 2026), 0.58 (Q4 2025), and 0.82 (Q3 2025), per Business Quant data.